Skip to content
Back to search results

Budget Impact Analysis (BIA)

Introduced by
Sullivan, Mauskopf, and colleagues (ISPOR task force)
Year
2005
Type
Method
Family
healthcare financial planning
Font size

What does it do?

Budget impact analysis estimates the financial consequences (net costs or savings) of implementing a new health technology in a specific healthcare system or population over a short time horizon (typically 1–5 years).

Distinct from cost-effectiveness analysis (which compares health outcomes per dollar), BIA answers a budgetary question: 'If we adopt this new drug/device, how much will it cost our health system next year?' Widely used by hospital procurement committees, insurance formularies, and government health budgets to assess financial feasibility and reimbursement decision.

The intuition behind the method

A hospital considers adopting a new cancer drug. Cost-effectiveness analysis shows it is cost-effective at $80,000 per QALY (below the threshold). But the hospital has a fixed annual budget. If the drug costs $150,000 per patient, the hospital oncology department treats 200 patients per year, and the drug replaces a $30,000 therapy, the incremental cost is $200 × ($150,000 − $30,000) = $24 million annually. That may exceed the hospital's pharmaceutical budget, requiring cuts elsewhere. BIA does not answer 'Is this drug worth the money?' (that is CEA). BIA answers 'How much will we spend if we use this drug, and can we afford it?' Two tools, complementary: CEA is an efficiency question; BIA is a feasibility/affordability question.

History

BIA emerged in the 1990s as health systems faced rising pharmaceutical costs. Sullivan and colleagues formalized methodology in the ISPOR 2012 task force report (Sullivan et al. 2014), which defined good practices and reporting standards. BIA became mandatory in Canada (CADTH, 2005), Australia (PBAC), UK (NICE, as ancillary to CEA), and much of Europe. By 2020, BIA was routine in reimbursement submissions worldwide. Recent trend: 'Budget Impact Modelling' advances include patient-level simulation (discrete event simulation) rather than cohort models, enabling heterogeneous treatment effects.

When to use it

When a new health technology is being considered for adoption and decision-makers need to know the budgetary impact. Standard requirement from payers: CADTH (Canada), NICE (UK), regional insurance funds demand BIA alongside CEA for reimbursement decisions. Use for: pharmaceutical pricing negotiations; device procurement decisions; formulary changes; service expansion planning; healthcare budget forecasting. Mandatory in most developed countries when submitting for reimbursement approval. Not needed for: academic research (non-applied); interventions with negligible cost differences; when budget is not a constraint.

Limitations and considerations

  • Short time horizon (1–5 years): does not capture long-term benefit (cost offsets from prevention, mortality reduction) that might justify initial budget increase. CEA (10+ year horizon) shows this better.
  • Static population: assumes population size and prevalence fixed; BIA does not account for aging population or disease prevalence trends.
  • Uptake forecasting is uncertain: market penetration depends on clinical factors (safety profile, efficacy in real world), adherence, and physician behavior. Forecast error propagates to budget impact.
  • Does not address equity: a low-cost generic and a high-cost branded drug may have similar BIA if uptake is low, but equity/access implications differ. BIA does not flag this.
  • Simplistic cost model: assumes direct medical costs only; does not capture spillovers (reduced lost work days, caregiver burden, quality of life) that CEA includes.

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Directly informs reimbursement/budgeting decisions: payers can see true financial impact and plan ahead, avoiding surprise budget overruns.
  • Complements CEA: even if drug is cost-effective, BIA reveals affordability constraints. Combined CEA + BIA gives complete picture.
  • Transparent, traceable: all cost and utilization assumptions are explicit, enabling scrutiny by finance teams and clinicians.
  • Supports negotiation: pharmaceutical companies can propose price reductions or managed entry agreements (e.g., 'We'll lower price to $1,500/patient, reducing budget impact by 25%') based on BIA results.

Applications

  • Pharmaceutical reimbursement negotiation: Manufacturer submits CEA (cost-effectiveness) + BIA (budget impact) to CADTH; if both favorable, drug is listed on formulary; price is negotiated to achieve target ICER and budget impact cap.
  • Hospital formulary committee: BIA of new cancer immunotherapy shows incremental cost $500K/year; committee approves adoption but requires offsetting cost reduction in another service line.
  • Public health program planning: Vaccination program BIA estimates cost per 100,000 population; compares to available budget and prioritizes age groups/risk groups based on affordability.
  • Insurance plan budgeting: Health insurer models impact of adding new biologic therapy to plan coverage; forecast members shifting to new drug; calculates premium increase needed to cover additional costs.
  • Health system merger/consolidation: BIA models impact of merged formularies on combined budget; identifies duplication costs and opportunities for leverage negotiation with manufacturers.

How it works

How it works

1

Step 1: Define the healthcare system (hospital, regional health authority, national insurer) and patient population (all cancer patients, type 2 diabetes in region, age 65+). Step 2: Define baseline scenario: Which treatments are currently used? What % of patients receive Drug A, Drug B, watchful waiting? What is the prevalence of the condition? Example: Type 2 diabetes affects 5% of region's population (10,000 people). Currently: 30% on metformin monotherapy (cost $200/year), 50% on metformin + sulfonylurea ($500/year), 20% on metformin + insulin ($1,500/year). Baseline annual budget = 10,000 × [(0.30 × $200) + (0.50 × $500) + (0.20 × $1,500)] = $6.5 million. Step 3: Define new scenario: A new SGLT2 inhibitor is approved (cost $2,000/year). Forecast market uptake: Year 1, 10% of patients switch to SGLT2i (displace existing therapy); Year 2, 25%; Year 3, 40% (ceiling at 40% as some remain on other drugs). Step 4: Quantify direct costs per patient: medication acquisition + dispensing + monitoring. SGLT2i requires annual kidney function testing (+ $100 lab cost). Calculate cost per treated patient. Step 5: Obtain cost data from pharmacy records, literature, expert opinion.

Formula
Define baseline treatment mix and population prevalence. Forecast population adoption of new technology (market penetration, displacement of old treatment). Identify direct medical costs per patient: medication, administration, monitoring, adverse event management, hospitalization if treatment fails. Collect cost data from formulary databases, hospital records, insurance claims.
2

Baseline annual budget (Year 0) = Population × Prevalence × Σ(treatment_i × cost_i). Example: 10,000 diabetics, baseline = $6.5 million (as above). Year 1 with SGLT2i: 10% of 10,000 = 1,000 patients on SGLT2i, 9,000 on other treatments. Cost = [1,000 × ($2,000 + $100)] + [remaining 9,000 on original mix, prorated]. If SGLT2i completely displaces sulfonylurea use (1,000 × $500 saved) but adds monitoring cost: Year 1 cost = $6.5M − (1,000 × $500) + (1,000 × $2,000) + (1,000 × $100) = $6.5M − $0.5M + $2M + $0.1M = $8.1M. Budget impact Year 1 = $8.1M − $6.5M = +$1.6M (cost increase). Year 2 (25% uptake): similar calculation yields higher absolute cost but may show some cost offsets if SGLT2i reduces hospitalizations (avoided diabetic ketoacidosis, heart failure admissions). Net budget impact = cumulative Year 1–5 incremental costs (discounted at 0–3%).

Formula
Calculate baseline budget = population × prevalence × treatment mix × cost per patient. Calculate new scenario budget with new technology at projected market share. Budget impact = new budget − baseline budget (net annual cost to payer or health system).
3

Positive budget impact = increased costs (spending pressure, requires budget reallocation or new funding). Negative budget impact = cost savings (budget relief, can fund other services or reduce payer contribution). Time to break-even: if SGLT2i prevents hospitalizations, cumulative averted costs may eventually offset drug cost premium; identify when net impact turns negative. Affordability assessment: Is the incremental cost sustainable? If health system can only absorb $500,000 new costs but BIA predicts +$1.6M, reimbursement may be conditional (e.g., 'Fund only if hospital redirects surgical efficiency savings' or 'Limit to high-risk patients'). Payer decision: 'Is this technology cost-effective AND affordable?' Both questions must be answered: CEA (is it worth the money?) + BIA (can we afford it?). A drug can be highly cost-effective but unaffordable if budget is constrained.

Formula
If budget impact > 0, new technology increases payer costs (spending pressure); if < 0, new technology saves costs (budget relief). Report time-to-break-even: years until cumulative savings offset upfront costs. Conduct sensitivity analysis on market uptake, cost assumptions. Report budget impact per treated patient. Assess affordability: can the health system absorb this cost while maintaining other services?

Common pitfalls

  • Misinterpreting negative budget impact: 'Drug saves money!' is appealing but may be misleading if savings are small and health gains uncertain. A drug that costs 10% less but is also 10% less effective is 'budget-neutral' but clinically inferior (CEA required).
  • Overstating market uptake: assuming all eligible patients will use new drug. In practice, uptake is 30–50% of eligible population due to clinical inertia, comorbidities, patient preference. Conservative uptake assumptions are prudent.
  • Ignoring cost offsets: if new drug reduces hospitalizations, BIA should include these avoided costs (not just acquisition cost). Failure to do so overstates budget impact.
  • Using list prices instead of actual prices: pharmaceutical companies often negotiate rebates, volume discounts, or confidential agreements. Using list price inflates true budget impact. Budgets must use realistic net prices.
  • Conflating BIA with value: positive budget impact is not a judgment that the technology is 'bad.' A cost-increasing but highly effective drug may be justified if health system prioritizes outcomes over cost-containment.

Frequently asked questions

How is 'market uptake' or 'market penetration' forecast for BIA?

Methods vary: (1) expert opinion (clinicians estimate what % of eligible patients will use new drug); (2) comparative analysis (lookup similar drug's adoption trajectory over 5 years in same market); (3) diffusion model (logistic curve fitting prior adoption patterns in market); (4) discrete choice model (survey clinicians/patients on willingness to switch). Uncertainty is high; BIA should test low, base, and high uptake scenarios in sensitivity analysis.

Should BIA include cost offsets from prevented complications (e.g., avoided strokes, hospitalizations)?

Yes, if data are available. If new drug reduces cardiac events by 20%, calculate hospitalization costs averted and include in BIA. However, quantifying offsets is challenging and requires modeling disease progression. Many BIAs conservatively exclude offsets (showing worst-case budget impact); if offsets are included, clearly document assumptions and cite source data.

What discount rate should be used in BIA?

Standard: 0–3% annually. BIA time horizons are short (1–5 years), so discounting is minimal. Most use 0% (undiscounted) for simplicity; 3% is standard if longer horizon (>5 years). Rationale: healthcare budgets are year-to-year; short-term impact matters. Contrast with CEA, which discounts 3–5% over 10+ years (long-term efficiency focus).

Can BIA be used to compare two new drugs with similar efficacy but different costs?

Yes. BIA will show which has lower budget impact. However, if two drugs are clinically equivalent, clinical choice is often cost-driven; BIA provides that cost signal. Complement with CEA to ensure both are cost-effective vs current standard; then BIA guides choice between two acceptable options.

How do managed entry agreements (MEAs) relate to BIA?

MEAs are pricing/reimbursement contracts that reduce budget impact. Examples: (1) Conditional coverage ('fund only for patients meeting criteria'), which limits uptake. (2) Price discounts ('Reduce price to $X per patient to achieve target budget impact'). (3) Outcomes-based rebates ('If drug fails to meet efficacy targets, manufacturer refunds difference'). Manufacturer and payer negotiate using BIA results: 'Current price + projected uptake = $5M budget impact; to achieve $2M, we need price cut to $X or restrict to subgroup Y.'

What is the difference between BIA and 'financial impact analysis'?

BIA is a specific methodology (Sullivan et al. guidelines) for healthcare. Financial impact analysis is broader, applied to any project (IT system, facility renovation) to forecast budget consequences. In healthcare context, BIA and financial impact analysis are synonymous; BIA is the standard term.

Related methods

Sources

  1. Sullivan, S. D., Mauskopf, J. A., Augustovski, F., et al. (2014). Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 17(1), 5-14.

    Open DOI reference
    Copied.
  2. Klok, R. M., Brouwers, J. R., Postma, M. J., et al. (2005). Budget-impact analysis: a systematic literature review of implementation studies. The Annals of Pharmacotherapy, 39(3), 518-526.

    Open publication reference
    Copied.
  3. Canadian Agency for Drugs and Technologies in Health (CADTH). (2017). Guidelines for the Economic Evaluation of Health Technologies: Canada (4th ed.). Ottawa: CADTH.

    Open publication reference
    Copied.